No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| SOPHSOPHiA GENETICS S.A. | 350.09M | 5.16 | -5.43 | 4.49% | -102.29% | -123.55% | 0.31 | |
| TEMTempus AI, Inc. | 11.91B | 68.92 | -14.97 | 30.38% | -18.45% | -40.15% | 8.31 | |
| WGSGeneDx Holdings Corp. | 3.16B | 109.28 | -56.33 | 50.79% | 0.52% | 0.71% | 0.47 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 179.32M | 212.19M | 234.69M | 202.57M | 305.45M |
| Revenue Growth % | - | 0.18% | 0.11% | -0.14% | 0.51% |
| Cost of Goods Sold | 175.3M | 228.8M | 261.44M | 112.56M | 111.05M |
| COGS % of Revenue | 0.98% | 1.08% | 1.11% | 0.56% | 0.36% |
| Gross Profit | 4.03M | -16.6M | -26.75M | 90.01M | 194.4M |
| Gross Margin % | 0.02% | -0.08% | -0.11% | 0.44% | 0.64% |
| Gross Profit Growth % | - | -5.12% | -0.61% | 4.36% | 1.16% |
| Operating Expenses | 246.02M | 429.55M | 640.9M | 270.6M | 217.61M |
| OpEx % of Revenue | 1.37% | 2.02% | 2.73% | 1.34% | 0.71% |
| Selling, General & Admin | 163.93M | 318.73M | 338.24M | 194.71M | 168.48M |
| SG&A % of Revenue | 0.91% | 1.5% | 1.44% | 0.96% | 0.55% |
| Research & Development | 72.7M | 105.16M | 86.2M | 58.27M | 45.72M |
| R&D % of Revenue | 0.41% | 0.5% | 0.37% | 0.29% | 0.15% |
| Other Operating Expenses | 9.39M | 5.66M | 216.46M | 17.63M | 3.41M |
| Operating Income | -241.99M | -446.15M | -667.65M | -180.6M | -23.21M |
| Operating Margin % | -1.35% | -2.1% | -2.84% | -0.89% | -0.08% |
| Operating Income Growth % | - | -0.84% | -0.5% | 0.73% | 0.87% |
| EBITDA | -230.26M | -424.34M | -608.34M | -146.86M | -1.26M |
| EBITDA Margin % | -1.28% | -2% | -2.59% | -0.73% | -0% |
| EBITDA Growth % | - | -0.84% | -0.43% | 0.76% | 0.99% |
| D&A (Non-Cash Add-back) | 11.73M | 21.81M | 59.31M | 33.73M | 21.95M |
| EBIT | -238.87M | -242.56M | -457.51M | -170.19M | -23.21M |
| Net Interest Income | -1.97M | -2.76M | -666K | 1.11M | -3.03M |
| Interest Income | 506K | 79K | 2.54M | 1.11M | 0 |
| Interest Expense | 2.47M | 2.83M | 3.21M | 0 | 3.03M |
| Other Income/Expense | 654K | 200.76M | 69.62M | 3.9M | -29.42M |
| Pretax Income | -241.34M | -245.39M | -598.03M | -176.69M | -52.63M |
| Pretax Margin % | -1.35% | -1.16% | -2.55% | -0.87% | -0.17% |
| Income Tax | 0 | 0 | -49.05M | -926K | -343K |
| Effective Tax Rate % | 1% | 1% | 0.92% | 0.99% | 0.99% |
| Net Income | -241.34M | -245.39M | -548.98M | -175.77M | -52.29M |
| Net Margin % | -1.35% | -1.16% | -2.34% | -0.87% | -0.17% |
| Net Income Growth % | - | -0.02% | -1.24% | 0.68% | 0.7% |
| Net Income (Continuing) | -241.34M | -245.39M | -548.98M | -175.77M | -52.29M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -146.94 | -74.93 | -53.63 | -7.23 | -1.94 |
| EPS Growth % | - | 0.49% | 0.28% | 0.87% | 0.73% |
| EPS (Basic) | -33.16 | -74.93 | -53.63 | -7.23 | -1.94 |
| Diluted Shares Outstanding | 1.68M | 3.28M | 10.24M | 24.31M | 26.89M |
| Basic Shares Outstanding | 1.68M | 3.28M | 10.24M | 24.31M | 26.89M |
| Dividend Payout Ratio | - | - | - | - | - |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 174.11M | 483.54M | 212.62M | 182.34M | 197.97M |
| Cash & Short-Term Investments | 108.13M | 400.57M | 137.4M | 130.15M | 141.19M |
| Cash Only | 108.13M | 400.57M | 137.4M | 99.68M | 85.21M |
| Short-Term Investments | 0 | 0 | 0 | 30.47M | 55.97M |
| Accounts Receivable | 32.33M | 26.56M | 43.34M | 32.82M | 37.63M |
| Days Sales Outstanding | 65.81 | 45.69 | 67.41 | 59.13 | 44.97 |
| Inventory | 24.96M | 33.46M | 13.66M | 8.78M | 10.65M |
| Days Inventory Outstanding | 51.98 | 53.37 | 19.08 | 28.46 | 35 |
| Other Current Assets | 4.12M | 3.8M | 6.39M | 1.96M | 1.08M |
| Total Non-Current Assets | 77.53M | 70.55M | 332.64M | 236.42M | 221.41M |
| Property, Plant & Equipment | 63.11M | 62.72M | 84.28M | 59.38M | 58.51M |
| Fixed Asset Turnover | 2.84x | 3.38x | 2.78x | 3.41x | 5.22x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 186.65M | 172.63M | 158.6M |
| Long-Term Investments | 10.83M | 900K | 900K | 0 | 0 |
| Other Non-Current Assets | 3.6M | 6.93M | 6.48M | 4.41M | 4.31M |
| Total Assets | 251.64M | 554.09M | 545.26M | 418.76M | 419.38M |
| Asset Turnover | 0.71x | 0.38x | 0.43x | 0.48x | 0.73x |
| Asset Growth % | - | 1.2% | -0.02% | -0.23% | 0% |
| Total Current Liabilities | 73.44M | 101.28M | 144.3M | 58.82M | 54.82M |
| Accounts Payable | 26.74M | 44.69M | 46.02M | 10.24M | 7.95M |
| Days Payables Outstanding | 55.67 | 71.3 | 64.24 | 33.2 | 26.14 |
| Short-Term Debt | 3.51M | 3.42M | 10.87M | 497K | 0 |
| Deferred Revenue (Current) | 1000K | 473K | 40K | 0 | 0 |
| Other Current Liabilities | 41.42M | 52.7M | 67.08M | 30.88M | 30.42M |
| Current Ratio | 2.37x | 4.77x | 1.47x | 3.10x | 3.61x |
| Quick Ratio | 2.03x | 4.44x | 1.38x | 2.95x | 3.42x |
| Cash Conversion Cycle | 62.12 | 27.77 | 22.24 | 54.39 | 53.83 |
| Total Non-Current Liabilities | 173.81M | 64.71M | 147.26M | 131.92M | 119.32M |
| Long-Term Debt | 18.97M | 11M | 6.25M | 52.69M | 51.91M |
| Capital Lease Obligations | 20.78M | 18.43M | 60.01M | 62.94M | 60.92M |
| Deferred Tax Liabilities | 0 | 0 | 56.98M | 1.56M | 965K |
| Other Non-Current Liabilities | 134.06M | 35.28M | 24.02M | 14.73M | 5.52M |
| Total Liabilities | 247.25M | 165.99M | 291.56M | 190.74M | 174.13M |
| Total Debt | 43.26M | 32.85M | 77.13M | 119.77M | 116.17M |
| Net Debt | -64.88M | -367.72M | -60.27M | 20.09M | 30.96M |
| Debt / Equity | 9.86x | 0.08x | 0.30x | 0.53x | 0.47x |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | -97.81x | -157.37x | -208.19x | - | -7.66x |
| Total Equity | 4.39M | 388.1M | 253.71M | 228.02M | 245.25M |
| Equity Growth % | - | 87.45% | -0.35% | -0.1% | 0.08% |
| Book Value per Share | 2.62 | 118.50 | 24.78 | 9.38 | 9.12 |
| Total Shareholders' Equity | 4.39M | 388.1M | 253.71M | 228.02M | 245.25M |
| Common Stock | 0 | 24K | 38K | 2K | 2K |
| Retained Earnings | -330.05M | -575.44M | -1.12B | -1.3B | -1.35B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 425K | 830K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | -93.13M | -190.43M | -319.15M | -180.15M | -28.5M |
| Operating CF Margin % | -0.52% | -0.9% | -1.36% | -0.89% | -0.09% |
| Operating CF Growth % | - | -1.04% | -0.68% | 0.44% | 0.84% |
| Net Income | -241.34M | -245.39M | -548.98M | -175.77M | -52.29M |
| Depreciation & Amortization | 11.73M | 21.81M | 59.31M | 35.83M | 21.95M |
| Stock-Based Compensation | 120.23M | 219.42M | 41.98M | -326K | 9.14M |
| Deferred Taxes | 0 | 0 | -49.12M | -926K | -343K |
| Other Non-Cash Items | 2.4M | -194.35M | 141.53M | -721K | 17.79M |
| Working Capital Changes | 13.85M | 8.08M | 36.13M | -38.24M | -24.75M |
| Change in Receivables | -10.61M | 5.54M | 5.53M | 10.26M | -5.42M |
| Change in Inventory | -8.98M | -10.62M | 4.6M | 975K | -2.58M |
| Change in Payables | 0 | 0 | 34.46M | -46.95M | -20.46M |
| Cash from Investing | -31.97M | -20.79M | -141.33M | -43.73M | -30.13M |
| Capital Expenditures | -24.09M | -9.4M | -14.32M | -5.71M | -5.49M |
| CapEx % of Revenue | 0.13% | 0.04% | 0.06% | 0.03% | 0.02% |
| Acquisitions | - | - | - | - | - |
| Investments | - | - | - | - | - |
| Other Investing | -7.88M | -11.39M | 0 | 0 | 0 |
| Cash from Financing | 129.06M | 493.73M | 197.31M | 186.24M | 44.16M |
| Debt Issued (Net) | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - |
| Other Financing | 0 | 64.51M | 2.95M | 285K | 891K |
| Net Change in Cash | - | - | - | - | - |
| Free Cash Flow | -125.1M | -211.22M | -333.48M | -185.86M | -33.99M |
| FCF Margin % | -0.7% | -1% | -1.42% | -0.92% | -0.11% |
| FCF Growth % | - | -0.69% | -0.58% | 0.44% | 0.82% |
| FCF per Share | -74.59 | -64.49 | -32.58 | -7.64 | -1.26 |
| FCF Conversion (FCF/Net Income) | 0.39x | 0.78x | 0.58x | 1.02x | 0.55x |
| Interest Paid | 1.75M | 2.75M | 1.93M | 3.04M | 6.68M |
| Taxes Paid | 0 | 349K | 1.24M | 1.47M | 1.17M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -5500% | -125.04% | -171.07% | -72.97% | -22.1% |
| Return on Invested Capital (ROIC) | - | - | -468.38% | -61.35% | -6.64% |
| Gross Margin | 2.25% | -7.82% | -11.4% | 44.43% | 63.64% |
| Net Margin | -134.58% | -115.64% | -233.91% | -86.77% | -17.12% |
| Debt / Equity | 9.86x | 0.08x | 0.30x | 0.53x | 0.47x |
| Interest Coverage | -97.81x | -157.37x | -208.19x | - | -7.66x |
| FCF Conversion | 0.39x | 0.78x | 0.58x | 1.02x | 0.55x |
| Revenue Growth | - | 18.33% | 10.6% | -13.69% | 50.79% |
| 2022 | 2024 | |
|---|---|---|
| Diagnostic Test | 227.33M | 302.16M |
| Diagnostic Test Growth | - | 32.91% |
| Diagnostic Test, Third Party Insurance | 173.62M | 234.7M |
| Diagnostic Test, Third Party Insurance Growth | - | 35.18% |
| Diagnostic Test, Institutional Customers | 46.12M | 65.11M |
| Diagnostic Test, Institutional Customers Growth | - | 41.17% |
| Product and Service, Other | 7.36M | 3.29M |
| Product and Service, Other Growth | - | -55.26% |
| Diagnostic Test, Self Pay | 7.59M | 2.34M |
| Diagnostic Test, Self Pay Growth | - | -69.11% |
GeneDx Holdings Corp. (WGS) reported $402.2M in revenue for fiscal year 2024. This represents a 124% increase from $179.3M in 2020.
GeneDx Holdings Corp. (WGS) grew revenue by 50.8% over the past year. This is strong growth.
Yes, GeneDx Holdings Corp. (WGS) is profitable, generating $2.1M in net income for fiscal year 2024 (-17.1% net margin).
GeneDx Holdings Corp. (WGS) has a return on equity (ROE) of -22.1%. Negative ROE indicates the company is unprofitable.
GeneDx Holdings Corp. (WGS) generated $15.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.